Patents for A61P 35 - Antineoplastic agents (221,099)
03/2011
03/03/2011US20110053937 Inhibitors of the Interaction Between MDM2 and P53
03/03/2011US20110053935 Fused pyridines active as inhibitors of c-met
03/03/2011US20110053934 Compounds and methods of treatment
03/03/2011US20110053932 Protein Kinase Inhibitors and Methods for Using Thereof
03/03/2011US20110053931 Quinoline compounds and methods of use
03/03/2011US20110053930 Inhibitors of the bmp signaling pathway
03/03/2011US20110053928 Pyrimidothienoindazoles
03/03/2011US20110053925 Hydroxamate-Based Inhibitors of Deacetylases
03/03/2011US20110053923 Chemical compounds 610
03/03/2011US20110053921 Hexahydrooxazinopterine compounds
03/03/2011US20110053915 HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM
03/03/2011US20110053911 Tricyclic derivatives as inhibitors of poly(adp-ribose) polymerase (parp)
03/03/2011US20110053907 Substituted pyrimidines and triazines and their use in cancer therapy
03/03/2011US20110053906 Protein kinase inhibitors and use thereof
03/03/2011US20110053905 Compounds as tyrosine kinase modulators
03/03/2011US20110053900 Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
03/03/2011US20110053897 Compounds and compositions as syk kinase inhibitors
03/03/2011US20110053893 Compounds and compositions as tlr activity modulators
03/03/2011US20110053882 Methods and compounds for preventing and treating a tumour
03/03/2011US20110053879 Picoplatin and amrubicin to treat lung cancer
03/03/2011US20110053878 Acid-sensitive linkers for drug delivery
03/03/2011US20110053876 macrolides and their use
03/03/2011US20110053873 Hsp90 inhibitors
03/03/2011US20110053870 Use of isothiocyanate derivatives as anti-myeloma agents
03/03/2011US20110053864 Compositions and methods for modulation of cell migration
03/03/2011US20110053863 Methods of using flt3-ligand in the treatment of cancer
03/03/2011US20110053862 Compositions comprising survivin sirna and methods of use thereof
03/03/2011US20110053861 Compositions comprising nuclear factor-kappa b (nf-kb) sirna and methods of use
03/03/2011US20110053856 Metabolite derivatives of the hdac inhibitor fk228
03/03/2011US20110053850 Doc1 compositions and methods for treating cancer
03/03/2011US20110053846 The use of gnrh antagonist peptide in the treatement of sex hormone-dependent diseases
03/03/2011US20110053842 Targeted therapeutics based on engineered proteins that bind egfr
03/03/2011US20110053833 Synthetic peptides and their use
03/03/2011US20110053260 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
03/03/2011US20110053259 Recombinant poxvirus expressing homologous genes inserted into the poxvirus genome
03/03/2011US20110053249 Adenoviruses Mutated In The VA Genes For Cancer Treatment
03/03/2011US20110053217 Polynucleotides encoding signal peptide-containing molecules
03/03/2011US20110052729 Pharmaceutical or nutraceutical composition
03/03/2011US20110052717 Slow release pharmaceutical composition made of microparticles
03/03/2011US20110052710 Novel nanoparticles for delivery of active agents
03/03/2011US20110052709 Novel nanoparticles for delivery of active agents
03/03/2011US20110052708 Methods and formulations for the delivery of pharmacologically active agents
03/03/2011US20110052704 Tocotrienol compositions
03/03/2011US20110052703 Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
03/03/2011US20110052697 Aptamer-Directed Drug Delivery
03/03/2011US20110052694 Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
03/03/2011US20110052677 Modulation of srpx2-mediated angiogenesis
03/03/2011US20110052672 Treatments of disease or disorders using nanoparticles for focused hyperthermia to increase therapy efficacy
03/03/2011US20110052668 Identification and Characterization of a Specific CCK-C Receptor Antibody for Human Pancreatic Cancer and Its Use for Early Detection and Staging of Pancreatic Cancer
03/03/2011US20110052667 Compositions and methods for inhibiting angiogenesis and tumorigenesis
03/03/2011US20110052659 Implants for administering substances and methods of producing implants
03/03/2011US20110052643 Compounds for inflammation and immune-related uses
03/03/2011US20110052642 Peripheral zone tumor cells, methods for their preparation and use
03/03/2011US20110052641 Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms
03/03/2011US20110052616 Biological materials and uses thereof
03/03/2011US20110052615 Tumour-specific animal proteins
03/03/2011US20110052614 Stat3 epitope peptides
03/03/2011US20110052610 Antibody composition exhibiting cellular cytotoxicty due to glycosylation
03/03/2011US20110052609 Magnetic transducers
03/03/2011US20110052607 Methods of diagnosing myelodysplastic syndrome (mds) or leukemia using nucleic acids or fragments encoding flt3 kinase
03/03/2011US20110052605 Assay for soluble cd200
03/03/2011US20110052603 method of treatment and agents useful for same
03/03/2011US20110052595 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
03/03/2011US20110052593 Breast cancer associated antigen
03/03/2011US20110052589 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
03/03/2011US20110052588 Method of treating hepatocellular carcinoma
03/03/2011US20110052586 Antibodies to an epitope of agr2, assays and hybridomas
03/03/2011US20110052584 Method of enhancement of cytotoxicity in antibody mediated immune responses
03/03/2011US20110052583 Pyridinone compounds
03/03/2011US20110052582 Humanized Anti-CDCP1 Antibodies
03/03/2011US20110052581 Use of picoplatin and cetuximab to treat colorectal cancer
03/03/2011US20110052580 Use of picoplatin and bevacizumab to treat colorectal cancer
03/03/2011US20110052579 Ligands of the Natural Killer (NK) Cell Surface Marker CD27 and Therapeutic Uses Thereof,
03/03/2011US20110052578 Compounds and Compositions as Protein Kinase Inhibitors
03/03/2011US20110052577 Antibodies
03/03/2011US20110052576 Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
03/03/2011US20110052575 Anti-vegf antibodies
03/03/2011US20110052574 Method of inhibition of leukemic stem cells
03/03/2011US20110052571 Method for treating idiopathic thrombocytopenic purpura using monoclonal antibodies
03/03/2011US20110052570 Method to prognose response to anti-egfr therapeutics
03/03/2011US20110052567 Methods Compositions, Uses, and Kits Useful for Vitamin D Deficiency and Related Disorders
03/03/2011US20110052563 Gonadal function improving agents
03/03/2011US20110052554 Methods for off-the- shelf tumor immunotherapy using allogeneic t-cell precursors
03/03/2011US20110052547 Rapamycin-resistant t cells and therapeutic uses thereof
03/03/2011US20110052546 Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation
03/03/2011US20110052540 Non-Aggregating Virus Formulation
03/03/2011US20110052539 Oncolytic rhabdovirus
03/03/2011US20110052538 Probiotic/non-probiotic combinations
03/03/2011US20110052535 Compositions for treating an inflammatory autoimmune condition
03/03/2011US20110052530 Adoptive cell therapy with young t cells
03/03/2011US20110052527 Imidazopyridinyl thiazolyl histone deacetylase inhibitors
03/03/2011US20110052525 Breaking Immunological Tolerance with a Genetically Encoded Unnatural Amino Acid
03/03/2011US20110052502 MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof
03/03/2011US20110052501 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
03/03/2011US20110052496 Hollow nanoparticles and uses thereof
03/03/2011US20110052494 H-antigen binding polypeptides and methods of use
03/03/2011US20110052493 Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-a of hmgb1 to prevent and/or antagonize pathologies induced by hmgb1
03/03/2011US20110052492 Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy
03/03/2011US20110052491 Gastrin releasing peptide compounds
03/03/2011US20110052489 Anti-CD19 Antibodies